Clinical Trial Applications: Filter, Search, and view applications
| # | Protocol No | Study Title | Investigator(s) & Site(s) | |
|---|---|---|---|---|
306. |
ECCT/17/10/01 | Neo-Fosfo Intravenous and Oral Fosfomycin in Hospitalised Neonates with Clinical Sepsis: an open-label safety and pharmacokinetics study |
Principal Investigator(s) 1. James A Berkley Site(s) in Kenya KEMRI-WTRP |
View |
307. |
ECCT/17/09/04 | A5354 A5354 Effect of Antiretroviral Treatment Initiated During Acute HIV-1 Infection on Measures of HIV-1 Persistence and on HIV-1-Specific Immune Responses |
Principal Investigator(s) 1. Brian Baker Site(s) in Kenya KISUMU CRS |
View |
308. |
ECCT/17/09/03 | A5354 Effect of Antiretroviral Treatment Initiated During Acute HIV-1 Infection on Measures of HIV-1 Persistence and on HIV-1-Specific Immune Responses |
Principal Investigator(s) 1. Deborah Langat Site(s) in Kenya Kenya Medical Research Institute Walter Reed Project Clinical Research Centre |
View |
309. |
ECCT/17/09/02 | WHO ACTION-I and ACTION-2 Trial A65913: A multi-country, multi-centre, two-arm, parallel, double-blind, placebo-controlled, randomized trial of antenatal corticosteroids for women at risk of imminent birth in the early preterm period in hospitals in low-resource countries to improve newborn outcomes A65916: A multi-country, multi-centre, two-arm, parallel, double-blind, placebo-controlled, randomized trial of antenatal corticosteroids for women at risk of imminent birth in the late preterm period in hospitals in low-resource countries to improve newborn outcomes |
Principal Investigator(s) 1. Frederick Were 2. John Kinuthia 3. Zahida Parveen Qureshi 4. Zahida Parveen Qureshi 5. Zahida Parveen Qureshi Site(s) in Kenya 1. Coast Provincial General Hospital (Mombasa Level 5 Hospital) (Mombasa county) 2. Kiambu Level 4 Hospital (Kiambu county) 3. Thika Level 5 Hospital (Kiambu county) 4. Nakuru Level 5 Hospital (Nakuru county) |
View |
310. |
ECCT/17/09/01 | HPTN 084 HPTN 084: A Phase 3 Double Blind Safety and Efficacy Study of Long-Acting Injectable Cabotegravir Compared to Daily Oral TDF/FTC for Pre-Exposure Prophylaxis in HIV-Uninfected Women |
Principal Investigator(s) 1. Samuel Gurrion Ouma Site(s) in Kenya KISUMU CRS |
View |